FINEARTS-HF trial results in clinically meaningful reduction in the composite endpoint of CV death EP News Bureau Aug 6, 2024 The study could be of high clinical value to cardiologists who are seeking an optimal treatment of choice for HF patients, which…
Bayer, Sun Pharma sign marketing and distribution pact for second brand of Finerenone EP News Bureau Jan 17, 2024 Sun Pharma to market the drug under the brand name Lyvelsa
Bayer submits application in EU for extension of finerenone to include early stages of CKD… EP News Bureau Mar 17, 2022 Regulatory submission is based on positive data from the pivotal phase-III FIGARO-DKD study, published in the 'New England Journal…
Bayer gets US FDA nod for KERENDIA (finerenone) to treat CKD associated with type 2 diabetes EP News Bureau Jul 10, 2021 It is a first-in-class nonsteroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR…